Overview

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.
Phase:
Phase 2
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Treatments:
Ranolazine